Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 1,700 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCTGet Rating) CEO Ron Bentsur acquired 1,700 shares of the firm’s stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average price of $19.36 per share, for a total transaction of $32,912.00. Following the completion of the transaction, the chief executive officer now directly owns 2,961,414 shares in the company, valued at $57,332,975.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ron Bentsur also recently made the following trade(s):

  • On Monday, May 16th, Ron Bentsur purchased 1,000 shares of Nuvectis Pharma stock. The stock was bought at an average price of $19.32 per share, for a total transaction of $19,320.00.
  • On Thursday, May 12th, Ron Bentsur purchased 12,245 shares of Nuvectis Pharma stock. The stock was bought at an average price of $16.99 per share, for a total transaction of $208,042.55.
  • On Monday, March 28th, Ron Bentsur purchased 4,000 shares of Nuvectis Pharma stock. The stock was bought at an average price of $7.05 per share, for a total transaction of $28,200.00.
  • On Thursday, March 17th, Ron Bentsur acquired 7,000 shares of Nuvectis Pharma stock. The stock was acquired at an average cost of $7.63 per share, with a total value of $53,410.00.

Shares of NASDAQ:NVCT traded down $0.38 during trading hours on Thursday, hitting $18.48. The company’s stock had a trading volume of 346 shares, compared to its average volume of 49,102. Nuvectis Pharma, Inc. has a 52 week low of $3.08 and a 52 week high of $20.92. The company’s fifty day moving average is $10.45.

Several large investors have recently bought and sold shares of the company. Ronit Capital LLP bought a new stake in shares of Nuvectis Pharma in the 1st quarter valued at about $4,076,000. Virtu Financial LLC bought a new position in shares of Nuvectis Pharma during the 1st quarter worth approximately $84,000. Finally, BlackRock Inc. acquired a new position in Nuvectis Pharma during the 1st quarter valued at approximately $59,000.

A number of research firms recently commented on NVCT. Roth Capital reaffirmed a “buy” rating on shares of Nuvectis Pharma in a research note on Sunday, April 17th. HC Wainwright boosted their price objective on shares of Nuvectis Pharma from $14.00 to $21.00 in a research report on Tuesday, May 10th.

Nuvectis Pharma Company Profile (Get Rating)

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases.

Featured Articles

Insider Buying and Selling by Quarter for Nuvectis Pharma (NASDAQ:NVCT)

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.